AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2951819 — intervention group
Group type: EXPERIMENTAL
Intervention: Duovent (ipratropium bromide 40 micrograms and fenoterol 100 micrograms)
Number of subjects: 21
Study 2951819 — intervention group
Group type: COMPARATOR
Intervention: Berodual (ipratropium bromide 20 micrograms and fenoterol 50 micrograms)
Number of subjects: 21
Study 2951819 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 21
Study 30549489 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC + aspirin (1,000 mg each)
Number of subjects: 24
Study 30549489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30549489 — intervention group
Group type: COMPARATOR
Intervention: NAC (1,000 mg)
Number of subjects: 24
Study 30549489 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (1,000 mg)
Number of subjects: 24
Study 26607938 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary nitrate (nitrate-rich beetroot juice)
Number of subjects: 69
Study 26607938 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nitrate-depleted beetroot juice)
Number of subjects: 69
Study 26607938 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary nitrate
Number of subjects: 69
Study 26607938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 24703391 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular polynucleotides (Condrotide)
Number of subjects: 72
Study 24703391 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid (Hyalubrix)
Number of subjects: 72
Study 22145767 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen matrix (CM)
Number of subjects: 15
Study 22145767 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 15
Study 20398037 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0429 200 mg b.i.d.
Number of subjects: 21
Study 20398037 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0429 1600 mg b.i.d.
Number of subjects: 21
Study 17631461 — intervention group
Group type: EXPERIMENTAL
Intervention: Real Acupuncture (RA)
Number of subjects: 18
Study 17631461 — intervention group
Group type: COMPARATOR
Intervention: Sham Acupuncture (SA)
Number of subjects: 18
Study 15652165 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketac Silver Aplicap (KSA)
Number of subjects: 187
Study 15652165 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebilda SC (RSC)
Number of subjects: 187
Study 15652165 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebilda D (RD)
Number of subjects: 187
Study 15652165 — intervention group
Group type: COMPARATOR
Intervention: Students
Number of subjects: 187
Study 15652165 — intervention group
Group type: COMPARATOR
Intervention: Dentists
Number of subjects: 187
Study 12085141 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 degrees anterior fundoplication
Number of subjects: 83
Study 10442881 — intervention group
Group type: EXPERIMENTAL
Intervention: Congenitally blind participants
Number of subjects: 36
Study 10442881 — intervention group
Group type: COMPARATOR
Intervention: Sighted participants (including blindfolded)
Number of subjects: 36
Study 10442881 — intervention group
Group type: EXPERIMENTAL
Intervention: Blind and sighted children who gestured
Number of subjects: 36
Study 7877098 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (10 mg/day)
Number of subjects: 109
Study 7877098 — intervention group
Group type: COMPARATOR
Intervention: Control (no pravastatin)
Number of subjects: 109
Study 2193045 — intervention group
Group type: EXPERIMENTAL
Intervention: Education programme (information booklet and demonstration)
Number of subjects: 45
Study 646625 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinitrochlorobenzene
Number of subjects: 23
Study 646625 — intervention group
Group type: COMPARATOR
Intervention: 5-Fluorouracil
Number of subjects: 23
Study 31470912 — intervention group
Group type: EXPERIMENTAL
Intervention: Intersectoral care management
Number of subjects: 398
Study 31470912 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 398
Study 28315568 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal tension glaucoma (NTG)
Number of subjects: 129
Study 28315568 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary open angle glaucoma (POAG)
Number of subjects: 129
Study 28315568 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (Control)
Number of subjects: 129
Study 26501862 — intervention group
Group type: EXPERIMENTAL
Intervention: Video interpretation
Number of subjects: 208
Study 26501862 — intervention group
Group type: COMPARATOR
Intervention: Telephone interpretation
Number of subjects: 208
Study 23343466 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibacterial hand cleanser
Number of subjects: 20
Study 23343466 — intervention group
Group type: EXPERIMENTAL
Intervention: Glove occlusion
Number of subjects: 20
Study 23343466 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibacterial hand cleanser + Glove occlusion
Number of subjects: 20
Study 23343466 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-exposure cream
Number of subjects: 20
Study 23343466 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-exposure cream
Number of subjects: 20
Study 23343466 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-exposure cream + Post-exposure cream
Number of subjects: 20
Study 23343466 — intervention group
Group type: COMPARATOR
Intervention: Sodium lauryl sulfate (SLS)
Number of subjects: 20
Study 21614939 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative medicine approach (six group sessions on nutritional manipulation, yoga techniques, journaling, plus nutritional supplements: fish oil, vitamin C, standardized hops extract)
Number of subjects: 154
Study 21614939 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative medicine approach
Number of subjects: 154
Study 21614939 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 154
Study 19548250 — intervention group
Group type: EXPERIMENTAL
Intervention: CAMHS outpatient treatment
Number of subjects: 215
Study 19548250 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist outpatient treatment
Number of subjects: 215
Study 19548250 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient treatment
Number of subjects: 215
Study 19548250 — intervention group
Group type: EXPERIMENTAL
Intervention: Support for parents from professionals and other parents
Number of subjects: 215
Study 19548250 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibling support
Number of subjects: 215
Study 19548250 — intervention group
Group type: COMPARATOR
Intervention: Generic CAMHS services
Number of subjects: 215
Study 16991107 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio‐taped‐‐patient given audiotape
Number of subjects: 425
Study 16991107 — intervention group
Group type: COMPARATOR
Intervention: Standard care control‐‐not audio‐taped
Number of subjects: 425
Study 16991107 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio‐taped‐‐no audiotape given
Number of subjects: 425
Study 16991107 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio‐taped‐‐patient offered choice of receiving audiotape or not
Number of subjects: 425
Study 15320690 — intervention group
Group type: EXPERIMENTAL
Intervention: Deceleration component (rapid deceleration to a stop within 6 m of the end of each sprint)
Number of subjects: 18
Study 15320690 — intervention group
Group type: COMPARATOR
Intervention: No deceleration zone
Number of subjects: 18
Study 15320690 — intervention group
Group type: EXPERIMENTAL
Intervention: Deceleration component (hypothetical extrapolation)
Number of subjects: 18
Study 11093063 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 171
Study 11093063 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 171
Study 9485979 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative administration of bupivacaine
Number of subjects: 80
Study 9485979 — intervention group
Group type: COMPARATOR
Intervention: Postoperative administration of bupivacaine
Number of subjects: 80
Study 8379174 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) retrograde injection
Number of subjects: 0
Study 8379174 — intervention group
Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 0
Study 3729020 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine infiltration
Number of subjects: 8
Study 3729020 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine with epinephrine infiltration
Number of subjects: 8
Study 3729020 — intervention group
Group type: COMPARATOR
Intervention: Saline infiltration
Number of subjects: 8
Study 3729020 — intervention group
Group type: COMPARATOR
Intervention: Saline with epinephrine infiltration
Number of subjects: 8
Study 30839100 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle-Specific Risk of Febrile Neutropenia after Chemotherapy score (CSRFENCE score)
Number of subjects: 4590
Study 30839100 — intervention group
Group type: EXPERIMENTAL
Intervention: CSRFENCE score
Number of subjects: 4590
Study 31671290 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopic myomectomy with MyoSure® morcellator
Number of subjects: 320
Study 30373778 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped-care intervention to prevent major depressive disorder (MDD)
Number of subjects: 236
Study 30373778 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 236
Study 30373778 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of incident depression
Number of subjects: 236
Study 27144850 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozanimod 1 mg
Number of subjects: 197
Study 27144850 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozanimod 0.5 mg
Number of subjects: 197
Study 27144850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study 24474034 — intervention group
Group type: EXPERIMENTAL
Intervention: E2/LNG Low TDS (4.4 mg E2 and 1.39 mg LNG)
Number of subjects: 68
Study 24474034 — intervention group
Group type: EXPERIMENTAL
Intervention: E2/LNG High TDS (4.4 mg E2 and 2.75 mg LNG)
Number of subjects: 68
Study 24474034 — intervention group
Group type: COMPARATOR
Intervention: E2 0.050 mg/24 hours TDS and 0.090 mg LNG oral tablet
Number of subjects: 68
Study 22676628 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral group intervention before IVF and ICSI procedures
Number of subjects: 188
Study 22676628 — intervention group
Group type: COMPARATOR
Intervention: Control group (no psychological intervention)
Number of subjects: 188
Study 20660689 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemonoxacin 750 mg
Number of subjects: 265
Study 20660689 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemonoxacin 500 mg
Number of subjects: 265
Study 20660689 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin 500 mg
Number of subjects: 265
Study 17685683 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast Water Therapy (CWT)
Number of subjects: 13
Study 17685683 — intervention group
Group type: COMPARATOR
Intervention: Passive Recovery (PAS)
Number of subjects: 13
Study 15638905 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin extended-release (XL) 4 or 8 mg once daily for 13 weeks
Number of subjects: 680
Study 15638905 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin standard 1-8 mg once daily for 13 weeks
Number of subjects: 680
Study 15638905 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo run-in period)
Number of subjects: 680
Study 11942178 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 0
Study 11942178 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant treatment (chemotherapy, radiotherapy, multimodal treatments)
Number of subjects: 0
Study 10091516 — intervention group
Group type: EXPERIMENTAL
Intervention: Home intravenous antibiotic therapy
Number of subjects: 14
Study 10091516 — intervention group
Group type: COMPARATOR
Intervention: Hospital intravenous antibiotic therapy
Number of subjects: 14
Study 7589048 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam 10 mg
Number of subjects: 12
Study 7589048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2082837 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotically induced analgesia
Number of subjects: 10
Study 368044 — intervention group
Group type: EXPERIMENTAL
Intervention: Trebenzomine
Number of subjects: 26
Study 368044 — intervention group
Group type: COMPARATOR
Intervention: Doxepin
Number of subjects: 26
Study 31924257 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase-change material based temperature-control liners for 6 months
Number of subjects: 0
Study 31924257 — intervention group
Group type: COMPARATOR
Intervention: Regular gel or silicone liners for 6 months
Number of subjects: 0
Study 31112620 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 5 mg twice/day
Number of subjects: 110
Study 31112620 — intervention group
Group type: COMPARATOR
Intervention: Lower than recommended dosing of apixaban
Number of subjects: 110
Study 31112620 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 mg twice/day
Number of subjects: 110
Study 31112620 — intervention group
Group type: COMPARATOR
Intervention: Recommended dosing of 5 mg twice/day
Number of subjects: 110
Study 27430990 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine lozenge (25 mg) administered as single dose to HNC patients with oral mucositis
Number of subjects: 25
Study 27430990 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine lozenge (25 mg) administered as multiple doses to HNC patients with oral mucositis
Number of subjects: 25
Study 27430990 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine lozenge (5, 10, 25, and 50 mg) administered as single dose to healthy individuals
Number of subjects: 25
Study 26237979 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-rapid reinforcing-reducing needling manipulation at Jiaji (EX-B 2) acupoint
Number of subjects: 60
Study 26237979 — intervention group
Group type: COMPARATOR
Intervention: Uniform reinforcing-reducing manipulation at various acupoints
Number of subjects: 60
Study 24252803 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory cueing during treadmill walking
Number of subjects: 20
Study 24252803 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-cued treadmill walking
Number of subjects: 20
Study 24252803 — intervention group
Group type: COMPARATOR
Intervention: Cued treadmill walking
Number of subjects: 20
Study 21848780 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational programme on disaster preparedness for pregnant women
Number of subjects: 488
Study 21848780 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational programme)
Number of subjects: 488
Study 18563473 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent training (PT)
Number of subjects: 127
Study 18563473 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent training combined with child therapy (PT + CT)
Number of subjects: 127
Study 18563473 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control (WLC)
Number of subjects: 127
Study 17274807 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Relapse Prevention (ERP) training for care coordinators
Number of subjects: 0
Study 17274807 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study 15178928 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 130
Study 15178928 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 130
Study 11878518 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 MAC nitrous oxide (n=9)
Number of subjects: 18
Study 11878518 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 MAC isoflurane (n=9)
Number of subjects: 18
Study 9633757 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,000 IU vitamin E orally per day
Number of subjects: 0
Study 7523775 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg estradiol valerate
Number of subjects: 23
Study 7523775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 6363985 — intervention group
Group type: EXPERIMENTAL
Intervention: tiropramide hydrochloride (300 mg daily for 30 days)
Number of subjects: 60
Study 6363985 — intervention group
Group type: COMPARATOR
Intervention: octylonium bromide (120 mg daily)
Number of subjects: 60
Study 6363985 — intervention group
Group type: EXPERIMENTAL
Intervention: tiropramide hydrochloride
Number of subjects: 60
Study 30694699 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE)
Number of subjects: 55
Study 30694699 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Exercise (RE)
Number of subjects: 55
Study 30694699 — intervention group
Group type: COMPARATOR
Intervention: Both AE and RE
Number of subjects: 55
Study 30014816 — intervention group
Group type: EXPERIMENTAL
Intervention: Bites from five NF135.C10-infected mosquitoes
Number of subjects: 24
Study 30014816 — intervention group
Group type: EXPERIMENTAL
Intervention: Bites from one or two NF135.C10-infected mosquitoes
Number of subjects: 24
Study 30014816 — intervention group
Group type: EXPERIMENTAL
Intervention: Bites from five NF166.C8-infected mosquitoes
Number of subjects: 24
Study 30014816 — intervention group
Group type: EXPERIMENTAL
Intervention: Bites from one or two NF166.C8-infected mosquitoes
Number of subjects: 24
Study 27049275 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate micro air pump suction
Number of subjects: 96
Study 27049275 — intervention group
Group type: COMPARATOR
Intervention: Intravenous drip of magnesium sulfate
Number of subjects: 96
Study 24917905 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (150 mg)
Number of subjects: 47
Study 24917905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 22350328 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentha crispa (24 mg)
Number of subjects: 60
Study 22350328 — intervention group
Group type: COMPARATOR
Intervention: Secnidazole (2,000 mg)
Number of subjects: 60
Study 20473047 — intervention group
Group type: EXPERIMENTAL
Intervention: SEMGAS biofeedback training plus functional restoration
Number of subjects: 0
Study 20473047 — intervention group
Group type: COMPARATOR
Intervention: Functional restoration only
Number of subjects: 0
Study 20473047 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal, pain-free participants)
Number of subjects: 0
Study 17381122 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried cranberry juice (DCJ) 1200 mg/day
Number of subjects: 65
Study 17381122 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried cranberry juice (DCJ) 400 mg/day
Number of subjects: 65
Study 17381122 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine samples from DCJ consumption
Number of subjects: 65
Study 17381122 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolites identified from DCJ consumption
Number of subjects: 65
Study 17852978 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual lifestyle counselling
Number of subjects: 176
Study 17852978 — intervention group
Group type: COMPARATOR
Intervention: Group-based counselling
Number of subjects: 176
Study 17852978 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Individual and Group-based counselling)
Number of subjects: 176
Study 15581197 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral salbutamol
Number of subjects: 780
Study 15581197 — intervention group
Group type: COMPARATOR
Intervention: Inhaled salbutamol
Number of subjects: 780
Study 11049910 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 8
Study 11049910 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of fluvoxamine and erythromycin
Number of subjects: 8
Study 11049910 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin alone
Number of subjects: 8
Study 11049910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8994706 — intervention group
Group type: EXPERIMENTAL
Intervention: HPCD (hemostatic puncture closure device)
Number of subjects: 100
Study 8994706 — intervention group
Group type: COMPARATOR
Intervention: Manual compression
Number of subjects: 100
Study 1732133 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrohydraulic lithotripter (MPL 9000; 16, 20, and 24 kV)
Number of subjects: 9
Study 1732133 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic lithotripter (Lithostar Plus; settings 5, 7, and 9)
Number of subjects: 9
Study 1732133 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezoelectric lithotripter (Piezolith 2300; settings 2, 3, and 4)
Number of subjects: 9
Study 1732133 — intervention group
Group type: COMPARATOR
Intervention: Visual analogue scale
Number of subjects: 9
Study 1732133 — intervention group
Group type: COMPARATOR
Intervention: McGill Pain Questionnaire
Number of subjects: 9
Study 1732133 — intervention group
Group type: COMPARATOR
Intervention: Somatosensory evoked potentials
Number of subjects: 9
Study 2485273 — intervention group
Group type: COMPARATOR
Intervention: Fibrinogen derivatives and platelet activation products in patients with fulminant hepatic failure
Number of subjects: 31
Study 2485273 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparinization before haemoperfusion
Number of subjects: 31
Study 2485273 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin and charcoal haemoperfusion
Number of subjects: 31
Study 2485273 — intervention group
Group type: COMPARATOR
Intervention: Fibrinogen derivatives and platelet activation products in patients with compensated chronic liver disease
Number of subjects: 31
Study 31012513 — intervention group
Group type: EXPERIMENTAL
Intervention: Current flare status assessment (urological or pelvic pain symptoms that are much worse than usual)
Number of subjects: 385
Study 31012513 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic pain and urological symptoms during flares
Number of subjects: 385
Study 31012513 — intervention group
Group type: EXPERIMENTAL
Intervention: Flare duration assessment
Number of subjects: 385
Study 31012513 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted analyses of flare risk factors
Number of subjects: 385
Study 28748081 — intervention group
Group type: EXPERIMENTAL
Intervention: 225 μg iodine as potassium iodide capsule daily for 6 months
Number of subjects: 0
Study 28748081 — intervention group
Group type: COMPARATOR
Intervention: 450 g of appropriately iodized salt (30‐40 μg I as KIO3/g of salt) weekly for household consumption for 6 months
Number of subjects: 0